Compare ADMA Biologics Inc (ADMA) vs Advanced Micro Devices (AMD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Advanced Micro Devices — how do they compare? ADMA Biologics Inc trades at $9.25 (market cap $2.13B), while Advanced Micro Devices trades at $510.76 (market cap $841.57B). The key difference: Advanced Micro Devices is far larger — about 395.1× ADMA Biologics Inc's market cap, and Advanced Micro Devices is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | AMD | |
|---|---|---|
Market Cap | $2.13B | $841.57B |
Sector | Health | Technology |
52-Week High | $20.38 | $580.91 |
52-Week Low | $7.60 | $137.82 |
Enterprise Value | $2.20B | $833.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
AMD trades at $552.05, up 6.61% today and near its 52-week high, with strong technical momentum and bullish moving averages. The company reported robust Q1 2026 earnings of $1.37 EPS, beating expectations, and shows accelerating revenue growth to $34.64 billion in 2025 with net income surging to $4.34 billion. Analyst sentiment remains overwhelmingly positive with 71% buy ratings.
AMD's AI-driven growth trajectory presents significant upside potential, though premium valuations (P/E 184) and intense semiconductor competition pose risks. The stock's technical strength and fundamental momentum support continued bullish sentiment, but investors should monitor execution against high expectations and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Advanced Micro Devices
Advanced Micro Devices, Inc. (AMD) produces semiconductor products and devices. The Company offers products such as microprocessors, embedded microprocessors, chipsets, graphics, video and multimedia products and supplies it to third-party foundries, as well as provides assembling, testing, and packaging services. AMD serves customers worldwide.
Read more on AMD →
